Treatment of rheumatoid arthritis
Open Access
- 15 December 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 63 (24) , 2451-2465
- https://doi.org/10.2146/ajhp050514
Abstract
Purpose. Current and investigational treatments of rheumatoid arthritis (RA) are described. Summary. The current therapies used to treat RA include nonsteroidal antiinflammatory drugs (NSAIDs), used for the management of pain and inflammation; disease-modifying antirheumatic drugs (DMARDs), used as first-line therapy for all newly diagnosed cases of RA; and biological-response modifiers, targeted agents that selectively inhibit specific molecules of the immune system. Glucocorticoids and other antirheumatic drugs are also used to treat RA. DMARDs include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. NSAIDs and glucocorticoids are effective in controlling the pain, inflammation, and stiffness related to RA. Unlike NSAIDs, they slow clinical and radiographic progression of RA. The biological-response modifiers include infliximab, etanercept, and adalimumab (inhibitors of tumor necrosis factor [TNF]-α); anakinra, a recombinant inhibitor of interleukin-1; abatacept, the first costimulation blocker; and rituximab, a chimeric anti-CD20 monoclonal antibody. Investigational therapies for RA include anti-interleukin-6-receptor monoclonal antibodies, new TNF-α inhibitors (including one for oral administration), and antibodies against proteins critical for B-cell function and survival. Data accumulated in the past decade favor early aggressive therapy for patients suspected of having RA, including early referral to a rheumatologist, new diagnostic techniques, and aggressive therapy with DMARDs, glucocorticoids, and biological agents. The benefits of this approach have been demonstrated in clinical trials. Conclusion. Pharmacologic treatments of RA include NSAIDs, glucocorticoids, DMARDs, and biological agents. With an improved understanding of the pathophysiology of RA and the evidence from various clinical trials with the agents, early aggressive therapy with a combination of drugs or biological agents may be warranted for the effective treatment of RA.Keywords
This publication has 136 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory DrugsNew England Journal of Medicine, 1999
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- Relative bioavailability of oral low dose methotrexateEuropean Journal of Clinical Pharmacology, 1988